Long-term study of SPN-817 for focal seizures
Treatments studied
Part of Brain & nervous system clinical trials.
This study gives SPN-817 to people who completed a prior study of the same drug, to see if it stays safe and works well over a longer time. You may qualify if you already finished that study and have stable seizure medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier SPN-817 study.
- You must be taking between 1 and 4 seizure medicines at the same dose as before.
- You cannot have any episodes that look like seizures but are not (like fainting or panic attacks).
- You cannot have had serious thoughts of suicide in the past study or at your first visit, or more than one suicide attempt in your lifetime.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
This trial looks at ways to diagnose and treat focal epilepsy that isn't controlled by medications. It includes patients with or without a visible brain lesion on imaging.
Hear when a new Focal Onset Seizures trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.